Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer
Sundeep Agrawal(Center for Drug Evaluation and Research), Andrea B. Apolo(National Institutes of Health), Jamie Marko(National Institutes of Health Clinical Center), V. Ellen Maher(United States Food and Drug Administration), Brian R. Lane(Grand Rapids Community College), Amna Ibrahim(Beni-Suef University), Lauren Kim(National Institutes of Health), Gideon M. Blumenthal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Elizabeth R. Plimack(Fox Chase Cancer Center), Harpreet Singh(United States Food and Drug Administration), Mohammadhadi Bagheri(National Institutes of Health Clinical Center), Robert G. Uzzo(American Urological Association), Naomi B. Haas(University of Pennsylvania), Richard Pazdur(United States Food and Drug Administration), Toni K. Choueiri(Harvard University), Venkatesh Krishnasamy(National Institutes of Health), Jonathan Coleman(Memorial Sloan Kettering Cancer Center), Ke Liu(Chinese Academy of Sciences), Hans J. Hammers(Southwestern Medical Center), Cynthia Chauhan(American Society of Clinical Oncology), Julia A. Beaver(Center for Drug Evaluation and Research), F Richardson Cross(United States Food and Drug Administration), Gennady Bratslavsky(SUNY Upstate Medical University)
Cited by 13
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k